An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.

Haematologica

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.

Published: December 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713566	PMC
http://dx.doi.org/10.3324/haematol.2022.281128	DOI Listing

Publication Analysis

open-label phase

phase i/ii

i/ii trial

trial determine

determine maximum

maximum tolerated

tolerated dose

dose investigate

investigate safety

safety pharmacokinetics

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!